Top Page
Iperionx Limited
(Sydney:IPX)
Iperionx Limited (IPX) vs. iShares MSCI Australia ETF (EWA)
Iperionx Limited Business Overview & Revenue Model
Iperionx Limited Financial Statement Overview
| Breakdown | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | -657.16K | -634.11K | -211.58K | -9.38K |
| EBITDA | -37.79M | -22.49M | -17.48M | -29.39M | -8.82M |
| Net Income | -35.35M | -22.23M | -25.93M | -21.52M | -14.43M |
Balance Sheet | |||||
| Total Assets | 105.03M | 55.44M | 22.80M | 9.91M | 2.79M |
| Cash, Cash Equivalents and Short-Term Investments | 54.81M | 33.16M | 11.94M | 5.67M | 1.70M |
| Total Debt | 3.93M | 1.49M | 975.31K | 543.03K | 475.65K |
| Total Liabilities | 12.59M | 4.10M | 2.24M | 2.49M | 762.50K |
| Stockholders Equity | 92.44M | 51.34M | 20.56M | 7.42M | 1.76M |
Cash Flow | |||||
| Free Cash Flow | -39.41M | -26.68M | -18.57M | -14.06M | -3.62M |
| Operating Cash Flow | -21.80M | -18.61M | -15.86M | -12.13M | -3.56M |
| Investing Cash Flow | -24.28M | -6.53M | -5.71M | -3.07M | 1.76M |
| Financing Cash Flow | 67.99M | 46.59M | 27.89M | 19.39M | 3.50M |
Iperionx Limited Technical Analysis
Iperionx Limited Risk Analysis
Iperionx Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
52 Neutral | AU$2.28B | -36.34 | -50.19% | ― | ― | -20.85% | |
51 Neutral | AU$204.10M | -21.90 | -8.25% | ― | ― | -55.56% | |
48 Neutral | AU$595.26M | -28.63 | -7.50% | ― | ― | 51.47% | |
44 Neutral | AU$360.87M | -12.32 | -45.39% | ― | ― | -91.89% | |
43 Neutral | AU$839.73M | -18.84 | -13.97% | ― | 620.73% | -21.19% | |
41 Neutral | AU$198.72M | 54.17 | -3.24% | 1.54% | 14.64% | -213.25% |
Iperionx Limited Corporate Events
IperionX Limited has issued 1,288,179 fully paid ordinary shares, adding to its existing class of securities quoted on the Australian Securities Exchange. The company confirmed the shares were issued without a prospectus under Australian corporations law and stated it remains compliant with its financial reporting and continuous disclosure obligations, with no excluded information, signaling regulatory adherence around the new equity issuance.
The move modestly expands IperionX’s equity base and may have implications for existing shareholders through dilution, while potentially supporting the company’s capital needs for ongoing operations or growth initiatives. By affirming compliance with reporting and disclosure rules, IperionX aims to reassure investors and regulators that the additional shares have been issued within the framework of Australian securities regulation, maintaining transparency in its capital management activities.
The most recent analyst rating on (AU:IPX) stock is a Hold with a A$6.00 price target. To see the full list of analyst forecasts on Iperionx Limited stock, see the AU:IPX Stock Forecast page.
Iperionx Limited has applied to the ASX for quotation of 1,273,179 ordinary fully paid shares under its IPX code, with an issue date of February 24, 2026. The shares are being issued in lieu of a cash settlement, indicating the company has chosen to satisfy a liability or obligation through equity rather than cash, which may conserve cash resources but dilute existing shareholders.
The most recent analyst rating on (AU:IPX) stock is a Hold with a A$6.00 price target. To see the full list of analyst forecasts on Iperionx Limited stock, see the AU:IPX Stock Forecast page.
IperionX Limited is a dual-listed company with ordinary shares traded on the ASX and ADSs on Nasdaq under the symbol IPX, providing investors access to its equity through both Australian and U.S. markets. The company’s share pricing reflects cross-border trading dynamics, with recent ASX and Nasdaq prices indicating active participation across exchanges.
The company is issuing 1,273,179 ordinary shares at $4.11 per share as part of a settlement agreement, replacing a cash payment obligation with equity. IperionX will not receive cash proceeds from this transaction, which slightly dilutes existing shareholders but allows the company to satisfy its settlement commitments without impacting its cash reserves.
The offering will settle around February 24, 2026, with the shares sold directly by the company rather than through underwriters or agents. This direct issuance structure simplifies the transaction and signals a targeted, negotiated resolution tied to the underlying settlement rather than a broad capital-raising effort.
The most recent analyst rating on (AU:IPX) stock is a Hold with a A$6.00 price target. To see the full list of analyst forecasts on Iperionx Limited stock, see the AU:IPX Stock Forecast page.
IperionX Limited has reported a change in director Vaughn Taylor’s indirect interest in the company’s securities, following an on-market sale of 150,000 fully paid ordinary shares by Nalaroo Holdings Pty Ltd, a related entity. The sale, valued at A$1,025,351 and conducted to satisfy tax obligations, reduces Taylor’s indirect holding to 973,457 shares while leaving his 84,771 restricted stock units unchanged, and signals a personal portfolio adjustment rather than a shift in the company’s strategic direction.
The transaction did not occur during a closed trading period, indicating it followed standard governance procedures and did not require special trading clearance. Stakeholders are likely to view the move as routine director dealing for tax purposes, with limited immediate implications for IperionX’s operational outlook or broader market positioning.
The most recent analyst rating on (AU:IPX) stock is a Hold with a A$6.00 price target. To see the full list of analyst forecasts on Iperionx Limited stock, see the AU:IPX Stock Forecast page.
IperionX Limited has appointed Louisa Martino as Company Secretary, effective February 16, 2026, bringing more than 15 years of company secretarial and corporate advisory experience, including work on corporate compliance, capital raisings and due diligence for listed entities. She replaces Gregory Swan, who is stepping down from the role and has been thanked by the board for his contributions.
From the same date, IperionX will relocate its registered office and principal place of business to a new address on Pitt Street in central Sydney, consolidating its corporate base in a key Australian financial hub. The changes underscore the company’s efforts to strengthen governance, streamline regulatory communications with the ASX and support its broader corporate and capital markets activities.
The most recent analyst rating on (AU:IPX) stock is a Hold with a A$6.00 price target. To see the full list of analyst forecasts on Iperionx Limited stock, see the AU:IPX Stock Forecast page.
IperionX Limited has disclosed a change in the equity interests held by director Todd Hannigan, following the vesting of part of his share-based remuneration. The director converted 159,333 restricted stock units into an equivalent number of ordinary shares at no cash consideration after satisfying service-based vesting conditions, increasing his direct and indirect holding to 25,403,109 shares while reducing his unvested RSUs to 454,464. The transaction, which did not occur during a closed trading period, reflects ongoing alignment of the director’s remuneration structure with shareholder interests but does not alter the company’s overall capital structure in a material way.
The most recent analyst rating on (AU:IPX) stock is a Hold with a A$7.50 price target. To see the full list of analyst forecasts on Iperionx Limited stock, see the AU:IPX Stock Forecast page.
IperionX Limited has issued 1,773,212 fully paid ordinary shares that form part of its existing class of securities quoted on the Australian Securities Exchange. The company confirmed that the issuance was conducted without a disclosure document under the relevant Corporations Act provisions, while affirming ongoing compliance with financial reporting and continuous disclosure obligations and stating there is no excluded information, signaling that the capital raising was completed within standard regulatory frameworks and without undisclosed material information for investors.
The most recent analyst rating on (AU:IPX) stock is a Hold with a A$7.50 price target. To see the full list of analyst forecasts on Iperionx Limited stock, see the AU:IPX Stock Forecast page.
Iperionx Limited has applied to the ASX for quotation of 1,773,212 new ordinary fully paid shares under the code IPX, issued on 3 February 2026. The additional quoted securities will expand the company’s listed share capital, potentially enhancing liquidity in its stock and providing further flexibility for capital management and investor participation.
The most recent analyst rating on (AU:IPX) stock is a Hold with a A$7.50 price target. To see the full list of analyst forecasts on Iperionx Limited stock, see the AU:IPX Stock Forecast page.
IperionX Limited says it is entering 2026 in a strong operational position as it scales commercial production of titanium at its Virginia Titanium Campus, aiming to re-shore and become the world’s lowest-cost producer of high-performance titanium for critical U.S. industries. The company highlights that its proprietary HAMR and HSPT technologies, now proven at commercial scale, will underpin a push this year to ramp deliveries, improve manufacturing efficiency, and supply key U.S. defense and industrial programs, while it advances plans for a sevenfold capacity expansion in Virginia to about 1,400 tons annually by mid-2027, positioning IperionX as a strategic domestic titanium supplier and cost leader.
The most recent analyst rating on (AU:IPX) stock is a Hold with a A$7.50 price target. To see the full list of analyst forecasts on Iperionx Limited stock, see the AU:IPX Stock Forecast page.
IperionX Limited reported that it has fully commissioned titanium powder and component manufacturing at its Virginia Titanium Manufacturing Campus and is expanding capacity with new presses, ISO 9001-certified quality systems and inventory build-up for both standard and military-grade titanium fasteners. The company is progressing toward a 1,400 tpa titanium production capacity by 2027, underpinned by approximately US$75 million in expansion capex largely backed by a US$47.1 million U.S. Department of War IBAS award, additional government funding and free titanium scrap feedstock, while advancing next‑generation continuous HAMR/HSPT production technologies in Halifax County and the fully permitted Titan Critical Minerals Project, leaving it with US$65.8 million in cash and US$46.5 million in reimbursable government grants to support its growth and strengthen U.S. defense and critical minerals supply chains.
The most recent analyst rating on (AU:IPX) stock is a Hold with a A$8.50 price target. To see the full list of analyst forecasts on Iperionx Limited stock, see the AU:IPX Stock Forecast page.
IperionX has secured a US$300,000 prototype purchase order from American Rheinmetall to produce 700 lightweight titanium components for U.S. Army heavy ground combat systems, with delivery expected within eight to nine months and the potential to scale into a larger supply agreement upon successful completion. The components will be manufactured in the United States using 100% recycled titanium feedstock processed via IperionX’s proprietary HAMR and HSPT technologies, which enable lower-cost, high-performance titanium capable of reducing component weight by 40–45% and improving vehicle agility, range and survivability. As the only domestic commercial-scale producer of primary titanium metal, IperionX is positioned to address U.S. defense and aerospace supply chain vulnerabilities, and this order advances U.S. government goals to reshore critical materials, lessen reliance on foreign titanium sources and expand domestic, low-carbon manufacturing capacity.
The most recent analyst rating on (AU:IPX) stock is a Hold with a A$7.00 price target. To see the full list of analyst forecasts on Iperionx Limited stock, see the AU:IPX Stock Forecast page.
IperionX Limited has received the final US$4.6 million tranche of a US$47.1 million award from the U.S. Department of War’s Industrial Base Analysis and Sustainment program, funding the scale-up of titanium production and advanced manufacturing at its Virginia Titanium Manufacturing Campus to a planned capacity of 1,400 metric tons per year. In a further boost to its supply chain position, the U.S. Government has also transferred about 290 metric tons of high-quality Ti64 titanium scrap to the company at no cost—equivalent to roughly 1.5 years of feedstock at current full operating capacity—underscoring federal efforts to build a resilient, low-cost domestic titanium platform and reducing IperionX’s reliance on imported material while supporting its role in the U.S. defense industrial base.
The most recent analyst rating on (AU:IPX) stock is a Hold with a A$7.50 price target. To see the full list of analyst forecasts on Iperionx Limited stock, see the AU:IPX Stock Forecast page.
IperionX Limited announced that all remaining vendor performance-linked securities issued in connection with its 2020 acquisition of the Titan Critical Minerals Project in Tennessee have expired, including 19.8 million Class B Performance Shares and a total of 8 million performance options across two classes. Following this expiry, the company detailed an updated capital structure comprising 336.3 million quoted ordinary shares and a suite of unquoted employee performance rights, restricted stock units and options with various strike prices and maturities, clarifying its current equity overhang for investors and simplifying its capital base after contingent vendor instruments have lapsed.
The most recent analyst rating on (AU:IPX) stock is a Buy with a A$9.90 price target. To see the full list of analyst forecasts on Iperionx Limited stock, see the AU:IPX Stock Forecast page.
IperionX Limited has reported a change in the securities held by director Todd Hannigan, detailing adjustments to his direct and indirect interests in the company’s shares and equity instruments. The filing shows the lapse of 1,260,000 unlisted Class B performance shares and 560,000 A$0.20 performance options, which converted into a single fully paid ordinary share, leaving Hannigan with an increased total of 25,243,776 ordinary shares while his performance share and option holdings were removed; the change was recorded as having no consideration and did not involve trading during a closed period, signalling an internal restructuring of his incentive-based holdings rather than a market transaction.
The most recent analyst rating on (AU:IPX) stock is a Buy with a A$9.90 price target. To see the full list of analyst forecasts on Iperionx Limited stock, see the AU:IPX Stock Forecast page.
IperionX Limited has issued 678,429 fully paid ordinary shares, which form part of its existing quoted class on the Australian Securities Exchange. The company confirmed that the issuance was conducted without a prospectus under the relevant exemptions of the Corporations Act, and stated it remains in compliance with its financial reporting and continuous disclosure obligations, with no excluded information that would need to be disclosed to investors at this time.
The most recent analyst rating on (AU:IPX) stock is a Buy with a A$9.90 price target. To see the full list of analyst forecasts on Iperionx Limited stock, see the AU:IPX Stock Forecast page.
Iperionx Limited has applied to the ASX for quotation of 678,429 new fully paid ordinary shares under its IPX ticker, following the conversion or exercise of existing options or other convertible securities. The modest increase in quoted share capital reflects ongoing capital management activity but does not, on the information provided, signal a major change in strategy or operations; it slightly expands the company’s free float and may marginally affect existing shareholders’ dilution and trading liquidity.
The most recent analyst rating on (AU:IPX) stock is a Buy with a A$9.90 price target. To see the full list of analyst forecasts on Iperionx Limited stock, see the AU:IPX Stock Forecast page.
IperionX Limited has notified the market of the issuance of new unquoted equity securities under its employee incentive scheme, including 59,000 performance rights expiring on 31 December 2025, 5,000 performance rights expiring on 31 December 2026, and 235,000 options expiring on 1 April 2027 with an exercise price of A$10.00. The securities are subject to transfer restrictions and will not be quoted on the ASX until those restrictions lapse, highlighting the company’s continued use of equity-based incentives to align staff interests with shareholders and potentially expanding its fully diluted capital base over time.
The most recent analyst rating on (AU:IPX) stock is a Buy with a A$9.90 price target. To see the full list of analyst forecasts on Iperionx Limited stock, see the AU:IPX Stock Forecast page.
Iperionx Limited has notified the market that it is issuing 130,875 unquoted restricted stock units (RSUs) under the ASX code IPXAP on 23 December 2025. The new equity issuance, disclosed via an Appendix 3G filing, modestly increases the company’s pool of unquoted securities and may be related to incentive or compensation arrangements, signalling continued use of equity-based instruments to support capital management and staff or executive alignment with shareholder interests.
The most recent analyst rating on (AU:IPX) stock is a Buy with a A$9.90 price target. To see the full list of analyst forecasts on Iperionx Limited stock, see the AU:IPX Stock Forecast page.
IperionX Limited has achieved ISO 9001 certification for its titanium manufacturing operations in Virginia, a significant milestone that validates the quality management processes as the company scales production. This certification is crucial for customer qualification and procurement across various sectors, including defense, aerospace, and automotive, and is expected to enhance the company’s operational integrity and secure long-term supply contracts.
The most recent analyst rating on (AU:IPX) stock is a Buy with a A$9.90 price target. To see the full list of analyst forecasts on Iperionx Limited stock, see the AU:IPX Stock Forecast page.
IperionX Limited has partnered with Carver Pump Company to expedite the production of critical titanium components for U.S. Navy ships. This collaboration aims to address supply chain constraints by reducing lead times for titanium parts from over a year to less than a week, utilizing IperionX’s low-cost titanium metal powder and advanced manufacturing capabilities. The successful prototyping and testing phase could lead to larger production agreements, enhancing naval shipbuilding and maintenance efficiency, and improving fleet readiness.
The most recent analyst rating on (AU:IPX) stock is a Buy with a A$9.90 price target. To see the full list of analyst forecasts on Iperionx Limited stock, see the AU:IPX Stock Forecast page.